Lupin Acquires Anti-Diabetes Trademarks to Enhance Indian Healthcare Portfolio

Addressing the unmet medical needs and providing effective and cost effective treatment to millions of diabetic patients in India, the company said it is acquiring anti diabetic trademarks from Boehringer Ingelheim.

Lupin Limited had earlier announced takeover of anti-diabetes trademarks from Boehringer Ingelheim International GmbH last Friday. They are GIBTULIO, GIBTULIO MET, and AJADUO. Lupin had acquired it to get stronger in the diabetes business in India. By the end of March 2006, the transfer of the trademark rights will be completed.

Boehringer Ingelheim has co-marketed GIBTULIO, GIBTULIO MET, and AJADUO in India since 2016. They act by providing very good glycemic control in adults suffering from type 2 diabetes mellitus. For example, the main active ingredient in these drugs, empagliflozin, has evidence of cardiovascular death and hospital admissions for heart failure in adults with chronic kidney disease.

This is an important step in fighting this health crisis that diabetes brings to an estimated 80 million adults in India. Lupin plans to innovate and offer affordable solutions for millions suffering from Diabetes related complications. Nilesh Gupta, Managing Director of the company, further emphasized the dedication by stating a commitment to the provision of healthcare solution delivery in high quality and strengthening its credentials not only as a leader in diabetes care but in healthcare solutions in general.

Speaking on the occasion, Rajeev Sibal, President, India Region Formulations at Lupin, said, "It is also important to make the health and medicines accessible to the masses, especially in a country where diabetes awareness and detection are low."